- Home
- NSPR vs EPIX Comparison
NSPR vs EPIX Comparison
Compare NSPR & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSPR
- EPIX
- Stock Information
- Founded
- NSPR 2005
- EPIX 2009
- Country
- NSPR United States
- EPIX Canada
- Employees
- NSPR N/A
- EPIX N/A
- Industry
- NSPR Medical/Dental Instruments
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- NSPR Health Care
- EPIX Health Care
- Exchange
- NSPR Nasdaq
- EPIX Nasdaq
- Market Cap
- NSPR 75.1M
- EPIX 75.9M
- IPO Year
- NSPR N/A
- EPIX N/A
- Fundamental
- Price
- NSPR $2.44
- EPIX $1.72
- Analyst Decision
- NSPR Strong Buy
- EPIX Hold
- Analyst Count
- NSPR 2
- EPIX 3
- Target Price
- NSPR $4.50
- EPIX $2.00
- AVG Volume (30 Days)
- NSPR 386.2K
- EPIX 55.5K
- Earning Date
- NSPR 08-05-2025
- EPIX 08-04-2025
- Dividend Yield
- NSPR N/A
- EPIX N/A
- EPS Growth
- NSPR N/A
- EPIX N/A
- EPS
- NSPR N/A
- EPIX N/A
- Revenue
- NSPR $7,027,000.00
- EPIX N/A
- Revenue This Year
- NSPR $4.85
- EPIX N/A
- Revenue Next Year
- NSPR $113.47
- EPIX N/A
- P/E Ratio
- NSPR N/A
- EPIX N/A
- Revenue Growth
- NSPR 8.49
- EPIX N/A
- 52 Week Low
- NSPR $1.99
- EPIX $1.40
- 52 Week High
- NSPR $3.80
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- NSPR 54.16
- EPIX 51.31
- Support Level
- NSPR $2.12
- EPIX $1.68
- Resistance Level
- NSPR $2.46
- EPIX $1.75
- Average True Range (ATR)
- NSPR 0.16
- EPIX 0.04
- MACD
- NSPR 0.01
- EPIX 0.00
- Stochastic Oscillator
- NSPR 73.33
- EPIX 62.50
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.